Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03660774 · ClinicalTrials.gov registry record

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia

A clinical trial of Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S.

Completed
Registry status
563
Enrollment target
20
Study locations

NCT03660774 is a study of Haemophilia A and Haemophilia B that has completed, run by Novo Nordisk A/S. The registered enrollment target is 563 participants, above the 155-participant average among 8 other Haemophilia A trials with a reported enrollment target (263% higher). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03660774, a study of Haemophilia A and Haemophilia B, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
563 participants
Enrollment target
20
Study locations

Study Summary

The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents. The eTHINK study is designed to understand whether advances in hemophilia treatment have removed any impact of hemophilia. If there still is an impact of hemophilia, the eTHINK study will help to identify which children or adolescents are still at risk, and how to screen other children. Participants and their child will participate in a comprehensive assessment of child's brain development, thinking and behavior through completing tests and questionnaires. There is only one study visit of 1 to 1.5 hours with no follow-up required

Conditions Studied

Haemophilia A Haemophilia B

Interventions

  • OTHER No treatment given

Study Locations (20)

California

  • Novo Nordisk Investigational Site - Los Angeles
  • Novo Nordisk Investigational Site - Orange
  • Novo Nordisk Investigational Site - San Diego

Michigan

  • Novo Nordisk Investigational Site - Ann Arbor
  • Novo Nordisk Investigational Site - Detroit

Colorado

  • Novo Nordisk Investigational Site - Aurora

District of Columbia

  • Novo Nordisk Investigational Site - Washington D.C.

Florida

  • Novo Nordisk Investigational Site - Tampa

Georgia

  • Novo Nordisk Investigational Site - Atlanta

Illinois

  • Novo Nordisk Investigational Site - Chicago

Indiana

  • Novo Nordisk Investigational Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 563 participants
Start Date 2018-09-27
Est. Completion 2019-10-11

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03660774

The ClinicalTrials.gov registry entry for NCT03660774 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 563 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 155-participant average among 8 other Haemophilia A trials with a reported enrollment target (263% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.

NCT03660774 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Michigan, Colorado.

Frequently Asked Questions

What is clinical trial NCT03660774 about?

NCT03660774 is a clinical study titled "A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia". The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents. The eTHINK study is designed to understand whether advances in hemophilia treatment have removed any impact of hemophilia...

What is the current status of trial NCT03660774?

This trial is currently completed. The enrollment target is 563 participants. The study started on 2018-09-27. Estimated completion is 2019-10-11.

What conditions does trial NCT03660774 study?

This clinical trial studies the following conditions: Haemophilia A, Haemophilia B.

What interventions are being tested in trial NCT03660774?

The interventions under investigation include: No treatment given (OTHER).

Who is sponsoring clinical trial NCT03660774?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03660774 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Haemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Haemophilia A

All registered trials for this condition

Haemophilia B

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.